Divestment
ImCheck
ImCheck Therapeutics is driving innovation in immune system modulation based on their experience in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules.
They are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.
Key Facts
- Sector
Life Sciences
- Country
France
- Fund
LSP 5
- Entry
2017
- Exit
2025
Website
Responsible Partner
News
Do You Want to Know More?
We are eager to explore how we can achieve great things together.